Last reviewed · How we verify
Peginterferon alfa-2a plus Adefovir — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Peginterferon alfa-2a plus Adefovir (Peginterferon alfa-2a plus Adefovir) — Ruijin Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Peginterferon alfa-2a plus Adefovir TARGET | Peginterferon alfa-2a plus Adefovir | Ruijin Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Peginterferon alfa-2a plus Adefovir CI watch — RSS
- Peginterferon alfa-2a plus Adefovir CI watch — Atom
- Peginterferon alfa-2a plus Adefovir CI watch — JSON
- Peginterferon alfa-2a plus Adefovir alone — RSS
Cite this brief
Drug Landscape (2026). Peginterferon alfa-2a plus Adefovir — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon-alfa-2a-plus-adefovir. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab